At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 18 enrolled
Drug / intervention
Phosphatidylserine-Omega3 (SharpPS™-Gold)dietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Center, Open-Label Study to Assess the Efficacy of SharpPS™-Gold in Elderly Subjects With Memory Impairment
In Brief
A Phase 4 clinical trial evaluating Phosphatidylserine-Omega3 (SharpPS™-Gold) for Memory Impairment. Completed, enrolled 18 participants across 1 site.
Detailed Summary
The primary objective of this trial is to assess the ability of Phosphatidylserine-Omega3 to improve cognitive performance in elderly subjects with memory impairment. This study is a single-center, open-label 15 weeks duration trial to assess efficacy of Phosphatidylserine-Omega3 in elderly subjects with memory impairment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMemory Impairment
CountriesIsrael
Collaborators--
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2008
Enrollment StartSep 2008
Primary CompletionMar 2009
Study CompletionApr 2009
TodayJul 2026
First PostedAug 15, 2008
Enrollment StartSep 1, 2008
Primary CompletionMar 1, 2009
Study CompletionApr 1, 2009
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 17.9 years ago
Interventions
Phosphatidylserine-Omega3 (SharpPS™-Gold)dietary
Treatment will consist of capsules containing 100 mg phosphatidylserine-Omega3. Dosage: 1 capsule X 3 times daily, with meals. Duration: 15 weeks